Separating Fact from Fiction in Regenerative Medicine
In this article for dvm360, Gallant Director of Veterinary Affairs Dr. Rebecca Windsor addresses some of the most common misconceptions about stem cell therapy in veterinary medicine—covering what current science, regulation, and clinical data actually support.
For many veterinarians, “stem cell therapy” still conjures the older model of autologous treatments—cells harvested from the patient, processed off-site, and reinjected days later. Dr. Windsor explains how the field has shifted toward allogeneic, ready-to-use mesenchymal stem cell (MSC) therapies, manufactured under FDA-regulated conditions for consistent quality, potency, and availability.
Clarifying the Science and the Standards
The article walks through key myths, including concerns over immune rejection, tumor formation, and whether intravenous administration is effective. Drawing on peer-reviewed research, Dr. Windsor explains how MSCs interact with the immune system, why they are generally well-tolerated, and how their paracrine effects can modulate inflammation and support healing without long-term engraftment.
She also addresses the regulatory landscape, noting that allogeneic MSC therapies are classified as drugs and must meet rigorous FDA safety, efficacy, and manufacturing standards—unlike most autologous products, which face minimal oversight.
Practical Implications for Veterinary Practice
Dr. Windsor highlights the advantages of allogeneic therapies for busy clinics: no anesthesia, no tissue collection, no specialized equipment—just a slow IV injection after a straightforward thaw-and-prepare process. She outlines potential applications in chronic and immune-mediated diseases such as feline chronic gingivostomatitis (FCGS), osteoarthritis, and chronic kidney disease, where early intervention may offer the greatest benefit.
Why This Matters
By demystifying the science and addressing outdated perceptions, Dr. Windsor helps equip veterinarians with accurate, actionable knowledge as regenerative medicine moves toward mainstream use. With client interest already high and FDA-reviewed products on the horizon, understanding the true capabilities—and limitations—of stem cell therapy will be essential for guiding informed treatment decisions.
From dvm360
Busting Myths Around Stem Cell Therapy
This content is for educational purposes only. The therapy discussed is investigational and not yet commercially available.
Vice President of Veterinary Affairs at Gallant
Dr. Rebecca Windsor, DVM, DACVIM, is a board-certified veterinary neurologist with over 20 years of clinical experience and a strong record of scientific publication. She joined Gallant in 2025 and serves as Vice President of Veterinary Affairs.
Dr. Windsor specializes in veterinary regenerative medicine, with a focus on advancing FDA-approved, off-the-shelf mesenchymal stem cell therapies for pets. She develops educational platforms that translate the science, safety, and clinical efficacy of stem cell therapy for veterinary professionals. Since 2019, she has served as a Clinician Scientist at Ethos Discovery, where she leads the neurology research portfolio.
